PCORI National Patient and Stakeholder Dialogue: BIO's Public Statement

Feb 26 2012


Safety Labeling: Establishing Timeframes for Implementation of Product Safety Labeling Changes

Feb 20 2012


USPTO Genetic Testing Study: BIO's Testimony

Feb 17 2012
If a poor patient in Nevada doesn’t have access to an advanced molecular diagnostic test, and right across the border in California a similar patient has access to the same test, there’s obviously something wrong with that, but how can that be a patent problem?

Sunshine: BIO submits comments to CMS on Physician Payment proposed rule

Feb 16 2012

EPA Should Deny Petition to Waive Renewable Fuel Standard Obligations

Feb 16 2012
The RFS and EPA’s consistent implementation are the fundamental policy drivers for the continued development of advanced biofuels and cellulosic biofuels. It provides industry and investors with the confidence of knowing that if they can produce advanced and cellulosic biofuels, the RFS will ensure market access for those types of fuels. 

2012 Special 301 Report: Biotech's International IP Issues

Feb 14 2012
BIO has identified the following countries of interest and recommends the following for our 2011 Special 301 submission.

Alzheimer’s Disease: BIO's Comments on the Draft Framework for the National Plan to Address Alzheimer’s Disease

Feb 7 2012


PDUFA V: Testimony to House Committee on Energy and Commerce, Subcommittee on Health

Jan 31 2012


Essential Health Benefit: BIO's Comments on the HHS Pre-rule Bulletin

Jan 30 2012


USPTO Satellite Offices: Biotechnology Hubs Ideal Place

Jan 29 2012